Strong earnings reports, but stock prices plummeted: Why is the market so pessimistic about Baiyunshan's recovery?

Ask AI · Why couldn’t Baiyunshan’s profit growth convert into cash inflows?

Recently, Guangzhou Baiyunshan, a publicly listed company under Guangzhou Pharmaceuticals Group (600332.SH), released its 2025 annual report: full-year revenue reached RMB 77.656 billion, up 3.55% year over year; attributable net profit to shareholders was RMB 2.983 billion, up 5.21% year over year. After last year’s performance fell back, it shows some signs of recovery.

At the same time, the company continues its steady dividend policy. It plans to pay RMB 4.5 in cash per 10 shares, with a full-year payout ratio of 46.32%, maintaining its consistent style of shareholder returns.

Baiyunshan’s dividend proposal source: Baiyunshan 2025 annual financial report

However, behind this “growing steadily” set of results, concerns about operating quality are gradually becoming apparent: weak growth in non-recurring adjusted net profit, operating cash flow turning from positive to negative, high-margin business performance under pressure, and R&D spending also declining. The mismatch between expansion in scale and improvement in efficiency reflects a marginal weakening in the ability of the core business to generate cash. After the annual report was released, the company’s share price dropped sharply as well, indirectly reflecting the market’s cautious stance on the sustainability of its growth.

The disconnect between profit recovery and cash collection

The most attention-grabbing change at Baiyunshan in recent years comes from a clear weakening of cash flow from operating activities. In 2025, net cash flow from operating activities was -RMB 232 million, while in 2024 it was still RMB 3.442 billion. Not only did it turn from positive to negative, but it also hit the lowest level in nearly five years.

If you look at a longer timeframe, this pressure has not appeared suddenly. From 2021 to 2024, Baiyunshan’s net cash flow from operating activities was RMB 5.673 billion, RMB 6.999 billion, RMB 4.104 billion, and RMB 3.442 billion, respectively. Overall, it showed a continuous downward trend, until a noticeable drop in 2025, when funding pressure became more concentrated.

In contrast, the profit side has shown different performance. From 2021 to 2023, attributable net profit was RMB 3.72 billion, RMB 3.967 billion, and RMB 4.056 billion, respectively—staying in growth. It fell to RMB 2.835 billion in 2024 and then only slightly rebounded to RMB 2.983 billion in 2025. On the surface, profits seem stable, but cash flow has continued to weaken—clearly diverging. This structural gap of “profit recovery but cash leakage” often indicates pressure in areas such as receivables collection, purchases, and working-capital management, and it directly affects the real quality of profits.

Baiyunshan financial data source: Baiyunshan 2025 annual financial report

From operating data, the reasons are not complicated. In 2025, revenue grew 3.55% year over year, but “cash received from selling goods and providing services” was RMB 75.0 billion, lower than RMB 75.826 billion in 2024. Revenue growth did not translate into cash inflows. Meanwhile, the spending side kept expanding: “cash paid for purchasing goods and receiving services” increased from RMB 61.848 billion to RMB 63.955 billion, and related other cash outflows also rose from RMB 2.87 billion to RMB 3.605 billion. The dual squeeze of reduced collections and increased spending compressed the space for operating cash flow, ultimately dragging the full-year figure into negative territory.

Baiyunshan cash flow statement source: Baiyunshan 2025 annual financial report

The balance sheet further reflects changes in capital occupation. As of end-2025, accounts receivable were RMB 16.849 billion, higher than RMB 15.726 billion in the prior year; advances to suppliers increased from RMB 0.578 billion to RMB 0.970 billion; and inventories also rose from RMB 12.812 billion to RMB 13.138 billion. The rise in accounts receivable and advances means more funds are tied up across upstream and downstream stages, and together with inventory occupation, working capital has been continuously locked. At the same time, both the accounts receivable turnover rate and the inventory turnover rate declined to some extent, meaning overall capital turnover efficiency also fell.

From quarterly data, cash flow shows some seasonal fluctuations. In Q1 2025, net operating cash flow was -RMB 3.897 billion. In Q2 to Q4, it rebounded to RMB 0.500 billion, RMB 1.425 billion, and RMB 1.739 billion respectively, showing a trend of sequential recovery by quarter. But it still did not turn positive for the full year, suggesting the issue is not just a timing mismatch; it more likely relates to slower receivables collection pace and changes in purchasing conditions, among other factors.

Baiyunshan’s key quarterly financial data source: Baiyunshan 2025 annual financial report

In addition, changes in finance expenses also indirectly reflect the situation of funds. In 2025, the company’s finance expenses increased 635.66% year over year, mainly because interest income fell significantly. This implies that the scale of funds available on the books to generate interest income decreased. This aligns with the pressure on operating cash flow.

Baiyunshan financial data source: Baiyunshan 2025 annual financial report

Overall, Baiyunshan’s cash flow has shifted from a previous marginal weakening to a more pronounced structural pressure. When revenue growth fails to drive cash back into the business, profit recovery cannot translate into real cash. The stability of the company’s endogenous capital-generation ability is also put to the test.

A scale supported by low-margin business, while high-margin segments show fatigue

The disconnect between Baiyunshan’s cash flow and profit mainly stems from an imbalance in its business structure. The company covers multiple segments, including modern Chinese medicine, pharmaceutical-tech, natural beverages, pharmaceutical distribution, and bio-innovation. But in 2025, each segment’s performance diverged clearly: growth mainly came from the low-margin pharmaceutical distribution segment, while the high-margin brand and industrial segments as a whole were under pressure.

Specifically, in 2025, the pharmaceutical distribution segment generated主营业务收入 (main business revenue) of RMB 56.983 billion, up 6.21% year over year. Its revenue share exceeded 70%, making it the main source of scale expansion. However, this segment’s gross margin was only 5.87%. With revenue representing roughly three-quarters, it contributed only about one-quarter of gross profit—its profitability is clearly weak.

At the same time, the modern Chinese medicine segment’s revenue was RMB 6.776 billion, down 6.54% year over year; the pharmaceutical-tech segment’s revenue was RMB 2.482 billion, down 4.13%; and the natural beverages segment’s revenue was RMB 9.672 billion, down slightly by 0.34%. These three major segments generally had gross margins in the 40% to 60% range, yet they also saw revenue declines, making it hard to offset the low-margin characteristics of the pharmaceutical distribution segment.

Baiyunshan main business revenue source: Baiyunshan 2025 annual financial report

At the product level, the split among core product varieties has intensified. Revenue from the once-important profit driver, JinGe (sildenafil citrate), fell 26.18% year over year, and XiaoChaiHu Granules saw a significant drop due to demand changes. Meanwhile, products such as Xiaoke Pills, Angong Niuhuang Pills, the Amoxicillin series, and the Baoji series maintained relatively fast growth, becoming phased supports. But the growth scale of any single product is still not enough to make up for the decline in core categories.

In terms of regional structure, the company’s revenue is highly concentrated in South China. In 2025, this region contributed more than 70% of revenue. Revenue from Hong Kong, China, Macau, China, and overseas markets grew 6.93% year over year, and the gross margin increased to 12.16%, up 4.49 percentage points from the prior year. However, total overseas revenue was only RMB 294 million, accounting for less than 1%. Overall scale remains limited.

Baiyunshan revenue by region source: Baiyunshan 2025 annual financial report

Profitability quality also faced pressure. In 2025, the company’s adjusted attributable net profit (扣非归母净利润) was RMB 2.363 billion, basically flat with the previous year. The rebound in attributable net profit depended to a large extent on non-recurring items. At the same time, the company’s operating costs increased 4.12% year over year, higher than the 3.55% growth rate of revenue. The main business gross margin was 16.24%, down year over year, meaning the gross profit space continued to narrow. Overall, the company displays a mixed structural characteristic of “brand business + commercial platform,” rather than relying on product and brand premium-driven profitability typical of conventional Chinese medicine companies.

Changes in R&D spending further heighten attention on long-term growth. In 2025, the company’s R&D spending was RMB 695 million, only 3.67% of revenue. The industry average R&D spending amount was RMB 1.851 billion, and Baiyunshan is far below this figure. Although the company has laid out more than 160 R&D projects in areas such as malignant tumors, chronic disease management, and major respiratory diseases, 1.1-class anti-tumor new drug BYS10 tablets entered the key phase of registration clinical trials; the freeze-dried human rabies vaccine (Vero cells) was approved for market launch; and multiple improved new drugs made progress—under a backdrop of reduced investment intensity, the impact of innovation outcomes offsetting pressure on traditional products and the low-margin expansion of commercial segments remains relatively limited.

Baiyunshan R&D expenses source: Baiyunshan 2025 annual financial report

Remodeling growth drivers amid scale expansion

Even though Baiyunshan has faced operating pressure, it continues to rely on support from Guangzhou Pharmaceuticals Group to push ongoing plans in products, channels, technology, internationalization, and capital operations. Centered on a transformation toward “modernization, technologization, digitalization, and internationalization,” it aims to reshape growth drivers.

In terms of business foundation, core segments still have some support. The natural beverage segment, with Wanglaoji as its core, has a gross margin of 45.33%, and its profit contribution from subsidiaries is relatively stable. Wanglaoji herbal tea has ranked first on the C-BPI index for the herbal tea industry for 9 consecutive years; in 2025, the brand score ranked first among non-alcoholic beverages. Following health consumption trends, the company launched products such as CiLingJi, LiXiaoJi, and electrolyte water, attempting to expand into new product categories.

The pharmaceutical distribution segment continues to expand its channel network. Core company Guangzhou Pharmaceutical has listed on the National Equities Exchange and Quotations (NEEQ), and it entered the East China market by acquiring 100% of Zhejiang Medical Instrument. By the end of 2025, the company’s pharmaceutical retail outlets increased to 167 stores, including 126 stores that obtained “double-channel” qualifications, with its channel system continuing to improve.

In technology and digitalization, the company keeps advancing platform development. In 2025, it added 1 national-level platform and 2 national-level “specialized and innovative” (小巨人) enterprises. The traditional Chinese medicine preparation transformation pilot platform led by Cizhilin Pharmaceutical was selected as part of the Ministry of Industry and Information Technology’s first batch of lists. Research results related to Zhongyi Pharmaceutical were published in a Nature sub-journal, showing some scientific research progress.

Digital transformation is also advancing in parallel. The company works around its top-level plan, cooperating with industry enterprises to build the R&D system and a smart supply chain. Zhongyi Pharmaceutical was selected as a Guangdong provincial advanced intelligent factory, and production and management steps are gradually upgrading toward digitalization.

On internationalization, the company continues pushing product registrations and brand overseas expansion. Xiaochaihu Granules obtained a registration certificate for Chinese patent medicine in Macau; Angong Niuhuang Pills obtained a registration certificate in Vietnam. On the brand side, Wanglaoji launched the international identifier “WALOVI,” and its products entered markets such as Germany and Australia. The pharmaceutical distribution segment relies on the Hengqin import/export platform to gradually build a system for importing drugs and medical devices and a supply chain services framework.

In capital operations, the company participates in setting up multiple industrial funds, focusing on innovative drugs and modern Chinese medicine, and it also strengthened its East China distribution network by having a fund acquire 11.04% of Nanjing Pharmaceutical. In addition, after the company acquired Fujian Caishantang, the number of Chinese time-honored brand names increased to 13, and it completed the Baiyunshan Hanfang mixed-ownership reform, optimizing its governance structure. In the same period, Guangzhou Pharmaceuticals Group established Guangzhou Pharmaceuticals Capital, further extending the capital platform’s functions.

Baiyunshan’s main funds source: Baiyunshan 2025 annual financial report

From the group level, Guangzhou Pharmaceuticals Group has proposed the “14th Five-Year Plan (十五五)” development strategy, planning to invest RMB 10 billion to RMB 15 billion in R&D, RMB 20 billion to RMB 30 billion in industrial investment and M&A, building a “4+4+X” industrial system, and提出 a goal of “recreating another Guangzhou Pharmaceuticals” by 2030. As the group’s core listed platform, Baiyunshan will play an important role in resource integration and industrial coordination, and its development direction will gradually shift from scale expansion toward quality improvement.

Overall, in 2025 the company achieved double growth in revenue and net profit, maintained its basic operating scale, and continued its stable dividend policy that returns value to shareholders. But at the same time, issues still remain, including operating cash flow turning negative, a higher reliance on the low-margin pharmaceutical distribution segment in business structure, high-margin product growth under pressure, and a decline in R&D spending.

In an environment of tightened healthcare insurance controls (医保控费), normalized centralized procurement (集采), and intensifying industry competition, the company’s growth model is facing pressure to adjust. The differences between revenue scale expansion and profitability quality and cash flow performance have also continuously increased the market’s focus on the company’s operating quality and long-term value. (Produced by “Wealth Management Weekly – Caishi Hui”)